Identification of residual breast tumour localization after neo-adjuvant chemotherapy using a radioactive 125 Iodine seed

Riet, Yvonne E A van; Maaskant, A.J.G.; Creemers, Geert-Jan; Warmerdam, L. J. C. van; Jansen, Frits H.; Velde, Cornelis J.H. van de; Rutten, H.J.T.; Nieuwenhuijzen, Grard A. P.

doi:10.1016/j.ejso.2009.10.009

Cited by 39 publications

(24 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The brands of the used 125 I‐seeds within this meta‐analysis were limited to: Best Iodine‐125 seed, Best Medical International, Inc. Springfield, VA, USA, distributed by MPM Medical, Freehold, NJ, USA (used by Sung et al) . BrachySource I‐125 seed, BARD Inc, Covington, USA (used by Gobardhan et al, Alderliesten et al, and Donker et al) . Iodine‐125 seed, Cardinal Health, Woodland Hills, CA, USA (used by Gray et al, Hughes et al) . Iodine‐125, Draximage, Montreal, Canada (used by Lovrics et al) . IsoSeed® 125, Bebig Isotopen‐und Medizin Technik, Berlin, Germany (used by Riet et al) . …”

Section: Resultsmentioning

confidence: 99%

“…Finally, 4208 patients in 16 articles were eligible for inclusion based on the outcome parameters ( Fig. 1, flow chart) [30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45]. After contact with the authors we concluded that only 12 articles included original patients, one article contained original patients and patients from previously reported studies, and three articles contained a patient population that overlapped with previously reported work.…”

Section: Included Articlesmentioning

confidence: 99%

“…The brands of the used 125 I-seeds within this meta-analysis were limited to: [35] The 125 I-seeds of the different brands vary little with respect to design, dose-rate constant, anisotropy function, radial dose function, and anisotropy factor. Additionally, all types are approximately of the same size (þÀ 4 mm long axis, 0.8 mm short axis).…”

Section: Primary and Secondary Outcomesmentioning

confidence: 99%

See 2 more Smart Citations

Heading toward radioactive seed localization in non-palpable breast cancer surgery? A meta-analysis

et al. 2014

View full text Add to dashboard Cite

Wire-guided localization is the most commonly used technique for intraoperative localization of non-palpable breast cancer. Radioactive seed localization (RSL) is becoming more popular and seems to be a reliable alternative for intraoperative lesion localization. The purpose of the present meta-analysis was to evaluate the use of RSL. Primary study outcomes were irradicality and re-excision rates. In total 3168 patients were included. The clinical adaptation shows growing confidence in RSL and further growth is expected.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Included Articlesmentioning

confidence: 99%

Section: Primary and Secondary Outcomesmentioning

confidence: 99%

See 1 more Smart Citation

Heading toward radioactive seed localization in non-palpable breast cancer surgery? A meta-analysis

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Seeds have a half-life of 60 days, theoretically allowing insertion months prior to surgery if required (e.g., before neoadjuvant chemotherapy). [7, 8] The feasibility of RSL has been reported in institutional series. [9, 10] A small multicenter randomized control trial of WL versus RSL demonstrated no difference in the rates of positive or close margins (p = 0.61), but surgery was shorter following seed localization (mean, 19.4 minutes versus 22.2 minutes, p < 0.001).…”

Section: Introductionmentioning

confidence: 99%

Radioactive Seed Localization Compared to Wire Localization in Breast-Conserving Surgery: Initial 6-Month Experience

et al. 2013

View full text Add to dashboard Cite

Introduction Wire localization (WL) of non-palpable breast cancers on the day of surgery is uncomfortable for patients and impacts OR efficiency. Radioactive seed localization (RSL) before the day of surgery avoids these disadvantages. In this study we compare outcomes of our initial 6-month experience with RSL to those with WL in the preceding 6 months. Methods Lumpectomies for invasive or intraductal cancers localized with a single 125iodine seed (January-June 2012) were compared to those using 1 wire (July-December 2011). Surgeons and radiologists did not change. Positive and close margins were defined as tumor on ink and tumor ≤1mm from ink, respectively. Demographic and clinical characteristics and outcomes were compared between RSL and WL patients. Results There were 431 RSL and 256 WL lumpectomies performed. Clinicopathologic characteristics did not differ between groups. Most seeds (90%) were placed before the day of surgery. Positive margins were present in 7.7% of RSL versus 5.5% of WL patients, and 16.9% of RSL versus 19.9% of WL had close margins (p=0.38). The median operative time was longer for lumpectomy and sentinel lymph node biopsy (SLNB) in the RSL group (55 versus 48 minutes, p<0.0001). There was no significant difference in the volume of tissue excised between groups. Conclusions In the first 6 months of RSL, operative scheduling was simplified, while rates of positive and close margins were similar to those seen after many years of experience with WL. Operative time was slightly longer for RSL lumpectomy and SLNB; we anticipate this will decrease with experience.

show abstract

“…Radioguided seed localization is also useful in the neoadjuvant setting. Because of the long half-life of the 125 I-seed (59 days), it can be placed prior to the start of the neoadjuvant chemotherapy while remaining traceable after completion of the chemotherapy regimen [15]. Migration of the seed is rare and high rates of radical excision have been reported both in primary surgery and after neoadjuvant chemotherapy [15,16].…”

Section: Radioguided Seed Localization (Rsl)mentioning

confidence: 99%

Multimodal imaging in radioguided surgery

KleinJan

Bunschoten

Brouwer

et al. 2013

Clin Transl Imaging

View full text Add to dashboard Cite

Radioguided surgery (RGS) utilizes radiolabeled tracers that accumulate in the lesion of interest following local or systemic administration. RGS is an expanding surgical guidance technology, but unfortunately most currently available radiotracers are unable to provide intraoperative optical information regarding the location of the lesion. In 2011, a new hybrid tracer (both radioactive and fluorescent) was introduced for sentinel lymph node detection. This hybrid tracer (indocyanine green99m Tcnanocolloid) has helped to generate a new hybrid surgical guidance concept, thereby expanding the traditional RGSbased approach. Based on its radioactive signature a hybrid tracer is able to preserve the ''traditional'' role for RGS. Furthermore, as an additional tool in the operating room, a hybrid tracer provides optical information via fluorescence guidance. This review discusses the most common RGS approaches. Different clinically used radioactive tracers and their potential hybrid derivatives are also discussed. Furthermore, the various imaging devices designed for radioactivity-based detection are reviewed in the context of generating hybrid-imaging modalities.

show abstract

Identification of residual breast tumour localization after neo-adjuvant chemotherapy using a radioactive 125 Iodine seed

Cited by 39 publications

References 29 publications

Heading toward radioactive seed localization in non-palpable breast cancer surgery? A meta-analysis

Heading toward radioactive seed localization in non-palpable breast cancer surgery? A meta-analysis

Radioactive Seed Localization Compared to Wire Localization in Breast-Conserving Surgery: Initial 6-Month Experience

Multimodal imaging in radioguided surgery

Contact Info

Product

Resources

About